
    
      A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid
      Aromatase Inhibitor-resistanced Late Stage Breast Cancer.The primary endpoints of the study
      is progression free survival (PFS). The secondary endpoints are overall response rate (ORR),
      overall survival (OS) and safety.
    
  